. 2021 Dec 3;7(3):e002019. doi: 10.1136/rmdopen-2021-002019

Table 1.

Characteristics of patients with SLE receiving booster vaccine

Patient	Age	Sex	Duration of SLE* (years)	Immunosuppressive treatments	Initial vaccine series	Booster vaccine type	Days from initial to booster vaccine	Anti-RBD pan-Ig¶ by Roche Elecys (U/mL)		Anti-RBD-IgG¶ by Abbott assay (AU/mL)		sVNT‡ (% inhibition)		IFN-γ ELISpot§ (SFC/10⁶ PBMCs)
Patient	Age	Sex	Duration of SLE* (years)	Immunosuppressive treatments	Initial vaccine series	Booster vaccine type	Days from initial to booster vaccine	Prebooster	Postbooster†	Prebooster	Postbooster†	Prebooster (%)	Postbooster (%)†	Postbooster†
1	27	Female	5	Azathioprine 100 mg/day Ciclosporin 100 mg/day Prednisolone 10 mg/day	CoronaVac	Pfizer	113	342	24 416	275	36 182	16.74	99.70	62
2	19	Female	0	Prednisolone 10 mg/day Hydroxychloroquine 1000 mg/week	CoronaVac	Pfizer	94	83	15 076	332	25 719	27.94	98.98	228
3	50	Female	24	Mycophenolate mofetil 1000 mg/day Prednisolone 10 mg/day Hydroxychloroquine 400 mg/week	CoronaVac	Pfizer	83	50	18 213	96	26 152	<1	99.42	88
4	50	Female	13	Prednisolone 5 mg/day Hydroxychloroquine 1400 mg/week	CoronaVac	ChAdOx1	86	21	6098	170	9756	4.79	99.19	414
5	41	Female	24	Prednisolone 5 mg/day Hydroxychloroquine 1400 mg/week	CoronaVac	Pfizer	92	32	21 759	104	34 784	<1	99.48	624
6	23	Female	17	Prednisolone 5 mg/day	CoronaVac	Pfizer	72	97	15 087	300	25 955	12.56	94.95	646
7	21	Female	4	Azathioprine 100 mg/week Prednisolone 2.5 mg/day Hydroxychloroquine 1000 mg/week	CoronaVac	Pfizer	97	434	85 024	916	80 051	74.93	99.48	1200
8	29	Female	8	Tacrolimus 5 mg/day Prednisolone 2.5 mg/day Hydroxychloroquine 400 mg/week	CoronaVac	Pfizer	92	NA	71 508	NA	96 572	NA	99.64	NA

*Systemic lupus erythematosus.

†14 days after booster vaccination.

‡SARS-CoV-2 Surrogate Virus Neutralization Test (NeutraLISA, Euroimmun, Lübeck, Germany) reported as % neutralisation.

§IFN-γ ELISpot reported as spot-forming cell per million peripheral blood mononuclear cells.

¶Anti-SARS-CoV-2 spike receptor binding domain (RBD) IgG antibody concentrations reported as.U/mL or AU/mL.

ELISpot, enzyme-linked immunosorbent spot; IFN-γ, interferon gamma; NA, not applicable; SFC, spot-forming cell; SLE, systemic lupus erythematosus.